1 elegantly addressed ageing detrimental influence on MuSCs in mice. Authors focused on the functional paracrine cross-talk between MuSCs and their regulatory cells in the skeletal muscle niche, namely fibro-adipogenic precursors (FAPs). Ageing significantly affects FAPs, as they fail to support MuSC renewal and differentiation and increase their pro-fibrotic commitment after muscle injury. On the contrary, young FAPs modulate the muscle healing system by stronger paracrine effects on MuSCs. Authors pin-pointed a molecular candidate in WISP1 (Wnt1 Inducible Signalling pathway Protein 1) within the secretome (i.e. the whole of cell-secreted paracrine molecules) of the injuryactivated and young FAPs, as further validated in WISP -/-mice with agerelated defects in muscle regeneration; paracrine therapy via systemic administration of recombinant WISP1 in aged mice showed to restore regenerative MuSC myogenesis. Therefore, targeting the signalling cross-talk within the MuSC niche via the FAP secretome, could help rejuvenating muscle healing, while counteracting age-related decay of regenerative potential. This study provides relevant insights for cardiac repair and regeneration as well. Ageing is a leading factor for cardiovascular disease, with the heart long being considered devoid of any regenerative capacity. Disease-or injury-related compensatory mechanisms include hypertrophy of resident cardiomyocytes and organ-wide remodelling, leading to heart failure. In the last years, growing interest has been dedicated to the identification of endogenous myocardial precursors with responsive restorative potential. Several populations of cardiac progenitor cells (CPCs) have been described with putative cardiovascular differentiation capacity; despite initial enthusiasm, an increasing body of works has been questioning the efficacy of CPC myogenic potential following injury. Indeed, in the adult injured heart, CPCs have shown to preferentially commit to a fibroblastic or vascular phenotype, with the few newly generated cardiomyocytes deriving from surviving pre-existing ones. 4 Deutsch et al. 5 clearly showed that myocardial infarction triggers resident murine cardiac stromal cells expressing an activated enhancer for the multipotent progenitor embryonic gene Nkx2.5. Although these cells retrieve expression of stem cell-and early cardiac transcription factors, they undertake a pro-fibrotic fate, rather than differentiating into new cardiomyocytes, suggesting that genetic restoration of the embryonic programme during adulthood might not be sufficient to reinstate developmental plasticity. Yet, CPCs have demonstrated to instruct the cardiac microenvironment by modulatory signalling and support local angiogenesis after injury 6 ; ex vivo administration of the CPC secretome (including extracellular vesicles) in rodent models of myocardial infarction results in cardiac function improvement with preservation of viable cardiomyocytes. 7 Hence, CPCs are likely to be considered endogenous regulatory supporting cells, rather than myogenic precursors; they are primed by a fibrogenic signature and endowed with relevant secretory potential, thus resembling the cardiac counterpart to skeletal muscle FAPs. Mammal cardiomyocytes become post-mitotic during the complete maturation from peri-natal age into adulthood, with meagre turnover potential during life. In contrast, the early neonatal mouse myocardium maintains efficient regeneration potential after extensive damage via dedifferentiation and proliferation of pre-existing cardiomyocytes; however, this restorative response is strictly limited to the first 7 days after birth, with clear transition to fibrosis/scarring soon afterwards. 8 The prompt peri-natal cardiomyocyte withdrawal from cell cycle into the differentiated resting state implies a drastic 'memory loss' of endogenous regenerative mechanisms, as cells 'age' into the mature functional phenotype. Emerging data have indicated some putative candidate targets to retrieve and 'rejuvenate' resident cardiomyocyte proliferative potential, such as the activation of cell cycle regulators or the inhibition of GSK-3 kinase signalling, a sensitive regulator of mammalian myocardial renewal. Notably, during cardiogenesis epicardial CPC provide paracrine signalling to the developing myocardium by means of mitogens influencing cardiomyocyte renewal; embryonic epicardial CPC contribute to cardiac fibroblasts, which support cardiomyocyte expansion; conversely, adult cardiac fibroblasts drive cardiomyocyte hypertrophy. 10 Such close crosstalk between cardiomyocytes and pro-fibrogenic CPC strongly resembles the paracrine relationship of skeletal muscle FAPs and MuSCs. Since WISP1 has been shown to play a crucial role in muscle regeneration, evaluation on its paracrine potential on the CPC-cardiomyocyte axis might offer valuable understandings for myocardial regeneration. Human recombinant WISP1 has been described to exert cardioprotective effects on isolated adult mouse cardiomyocytes experiencing anthracycline-induced cardiotoxicity, via inhibition of GSK-3b phosphorylation with b-catenin nuclear translocation. 11 Pharmacological blocking of GSK-3 promotes proliferation in human neonatal cardiomyocytes by up-regulating cell cycle and cytokinesis mechanisms via canonical Wnt pathway 12 ; thus, it is reasonable to think that WISP1 might also impact myocardial renewal. In stark contrast, adult rodents infused with Angiotensin-II show increased WISP1 expression in proliferative cardiac fibroblasts resulting in myocardial hypertrophy and activation of fibrosis. 13 By acting as pro-mitogenic and pro-survival paracrine effector by cardiac cell type-specific manner, WISP1 exerts complex biological effects, acting as friend or foe. Therefore, it might be interesting to assess its possible role in rejuvenating adult cardiomyocyte cell cycle progression when secreted by embryonic/peri-natal CPC compared to adult ones.
Lukjanenko et al. also demonstrated that skeletal muscle FAPs modulate the expression of the PDGFRa gene intronic variant (PDGFRaÀIn) as they age; PDGFRaÀIn prevents FAP skewing to fibrotic cells and it gets reduced in elderly and failing progenitors. Endogenous CPC have been described as PDGFRa-positive stromal cells, 14 contributing to ventricle fibrofatty scarring when impaired during arrhythmogenic cardiomyopathy. 15 Then, profiling PDGFRaÀIn modulation during CPC ageing could offer meaningful information as therapeutic target to limit unnecessary fibrosis. This body of work endorses the relevance of the paracrine modulation of the tissue microenvironment to inhibit functional ageing. Tissue rejuvenation might be pursued by stimulating endogenous cells via suitable paracrine instruction, rather than by coercing their genome by means of reprogramming or by replacing them through cell transplantation. Since increasing evidences indicates that restoration of resident cardiomyocyte proliferation represents the primary therapeutic mechanism for heart regeneration, results from Lukjanenko et al. might offer useful insights in the cardiac scenario. Rejuvenation of the CPC secretome might offer a putative working strategy to unlock resident cardiomyocyte renewal and provide fertile soil for a good seed. Hence, reinstating the developmental CPC-cardiomyocyte molecular cross-talk during adulthood might help growing old, while staying young at heart. 
